Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Khalid O. AlfaroukInstitute of Endemic Diseases, University of Khartoum, Khartoum, SudanC C StockUniversity of Münster, Münster, GermanySophie TaylorSchool of Veterinary Medicine and Science, University of Nottingham, Nottingham, UKMegan WalshSchool of Veterinary Medicine and Science, University of Nottingham, Nottingham, UKAbdel Khalig MuddathirFaculty of Pharmacy, University of Khartoum, Khartoum, SudanDaniel VerduzcoH. Lee Moffitt Cancer Center, Tampa, FL USAAdil H. H. BashirInstitute of Endemic Diseases, University of Khartoum, Khartoum, SudanOsama Y MohammedKing Saud University, Riyadh, Kingdom of Saudi ArabiaGamal Osman ElhassanUneizah Pharmacy College, Qassim University, AL-Qassim, Kingdom of Saudi Arabia ; Faculty of Pharmacy, Omdurman Islamic University, Khartoum, SudanSalvador HarguindeyStephan J. ReshkinDepartment of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, ItalyMuntaser E. IbrahimInstitute of Endemic Diseases, University of Khartoum, Khartoum, SudanCyril RauchSchool of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK
2015en
ABI
Abstract
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.
Identifiers
Citations and references
Cited by 30 references